Patents by Inventor Philip Lienau

Philip Lienau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PTEFb inhibiting macrocyclic compounds
    Patent number: 11242356
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 8, 2022
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
  • 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
    Publication number: 20210353630
    Abstract: The present invention includes name compounds of general formula (I): (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.
    Type: Application
    Filed: July 30, 2021
    Publication date: November 18, 2021
    Applicants: BAYER AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC.
    Inventors: Stefan Nikolaus GRADL, Manuel ELLERMANN, Philip LIENAU, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU
  • Compounds, compositions and methods for cancer treatment
    Patent number: 11142522
    Abstract: The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: October 12, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Timothy A. Lewis, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Manuel Ellermann, Philip Lienau, Knut Eis, Antje Margret Wengner, Charlotte Christine Kopitz, Martin Lange
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT
    Publication number: 20210236504
    Abstract: The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
    Type: Application
    Filed: January 28, 2021
    Publication date: August 5, 2021
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: TIMOTHY A. LEWIS, ALEX BURGIN, MONICA SCHENONE, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, LUC DE WAAL, ANTJE MARGRET WENGNER, KNUT EIS, PHILIP LIENAU, ULRIKE SACK, MARTIN LANGE
  • Macrocyclic indole derivatives
    Patent number: 10981932
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical 2019 compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 20, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren
  • Compounds, compositions and methods for cancer patient stratification and cancer treatment
    Patent number: 10966986
    Abstract: The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: April 6, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE INC.
    Inventors: Timothy A. Lewis, Alex Burgin, Monica Schenone, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Luc De Waal, Antje Margret Wengner, Knut Eis, Philip Lienau, Ulrike Sack, Martin Lange
  • 4-(3-AMINO-6-FLUORO-1H-INDAZOL-5-YL)-1,2,6-TRIMETHYL-1,4-DIHYDROPYRIDINE-3,5-DIC ARBONITRILE COMPOUNDS FOR TREATING HYPERPROLIFERATIVE DISORDERS
    Publication number: 20210047297
    Abstract: The present invention covers 4-(3-amino-6-fluoro-1H-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dicarbonitrile compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases.
    Type: Application
    Filed: March 25, 2019
    Publication date: February 18, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Volker SCHULZE, Tobias HEINRICH, Clara CHRIST, Hans BRIEM, Adelaide Clara FARIA ALVARES DE LEMOS, Benjamin BADER, Simon HOLTON, Ulf BÖMER, Philip LIENAU, Lara Patricia KUHNKE
  • Heteroarylbenzimidazole compounds
    Patent number: 10894784
    Abstract: The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: January 19, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Volker Schulze, Tobias Heinrich, Florian Prinz, Julien Lefranc, Jens Schröder, Anne Mengel, Wilhelm Bone, Joszef Bálint, Antje Margret Wengner, Knut Eis, Horst Irlbacher, Marcus Koppitz, Ulf Bömer, Benjamin Bader, Hans Briem, Philip Lienau, Clara Christ, Detlef Stöckigt, Roman Hillig
  • 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES
    Publication number: 20200383991
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 10, 2020
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
  • DIHYDROOXADIAZINONES
    Publication number: 20200369633
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 2, 2018
    Publication date: November 26, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS
    Publication number: 20200347079
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: March 22, 2018
    Publication date: November 5, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich LÜCKING, Daniel HOG, Clara CHRIST, Ulrike SACK, Franziska SIEGEL, Philip LIENAU, Nicolas WERBECK
  • 2-(morpholin-4-yl)-1,7-naphthyridines
    Patent number: 10772893
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 15, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
  • 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER
    Publication number: 20200247783
    Abstract: The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I): The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I):
    Type: Application
    Filed: August 2, 2018
    Publication date: August 6, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Detlev Sülzle, Timothy Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson
  • 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
    Patent number: 10729680
    Abstract: The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: August 4, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Marcus Koppitz, Julien Lefranc, Lars Wortmann, Antje Margret Wengner, Gerhard Siemeister, Ulf Bömer, Benjamin Bader, Philip Lienau, Hans Schick
  • Macrocyclic sulfondiimine compounds
    Patent number: 10717749
    Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 21, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Jens Geisler, Daniel Hog, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi, Simon Anthony Herbert, Gerhard Siemeister, Nicolas Werbeck
  • NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS
    Publication number: 20200123174
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: March 22, 2018
    Publication date: April 23, 2020
    Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
  • Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases
    Patent number: 10604532
    Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: March 31, 2020
    Assignees: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion Hitchcock, Anne Mengel, Vera Pütter, Gerhard Siemeister, Antje Margret Wengner, Hans Briem, Knut Eis, Volker Schulze, Amaury Ernesto Fernandez-Montalvan, Stefan Prechtl, Simon Holton, Jörg Fanghänel, Philip Lienau, Cornelia Preusse, Mark Jean Gnoth
  • MACROCYCLIC INDOLE DERIVATIVES
    Publication number: 20200087322
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 17, 2017
    Publication date: March 19, 2020
    Inventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER TREATMENT
    Publication number: 20200062741
    Abstract: The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.
    Type: Application
    Filed: February 1, 2018
    Publication date: February 27, 2020
    Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: TIMOTHY A. LEWIS, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, MANUEL ELLERMANN, PHILIP LIENAU, KNUT EIS, ANTJE MARGRET WENGNER, CHARLOTTE CHRISTINE KOPITZ, MARTIN LANGE
  • Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors
    Patent number: 10487092
    Abstract: The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: November 26, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Anja Giese, Ulrich Klar, Keith Graham, Georg Kettschau, Detlev Sülzle, Philip Lienau, Kirstin Petersen, Julien LeFranc, Nicole Schmidt